Search
Hidradenitis Suppurativa (HS) Clinical Trials
A listing of 4 Hidradenitis Suppurativa (HS) clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 4 of 4
There are currently 4 active clinical trials seeking participants for Hidradenitis Suppurativa (HS) research studies. The states with the highest number of trials for Hidradenitis Suppurativa (HS) participants are Florida, Ontario, California and Texas.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Type 2 Diabetes Clinical Trial
Recruiting
Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.
Conditions:
Type 2 Diabetes
Diabetes Mellitus Type 2 in Obese
Diabetes Type Two
Type 2 Diabetes Mellitus
Diabete Type 2
Featured Trial
Crohn's Disease Clinical Study
Recruiting
Help us study a potential new way to treat Crohn's disease. We are seeking adults living with Crohn's disease to join our latest clinical trial to help us learn more. Eligible participants will receive study-related treatment, assessments, and care at no cost. You will also receive reimbursement for travel while participating. Health insurance is not required to take part.
Conditions:
Crohn's Disease
Crohn Disease
Crohns Disease
Crohn's Disease (CD)
Crohn Colitis
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
Recruiting
The purpose of this study is to evaluate long-term safety and efficacy of povorcitinib in participants with moderate to severe hidradenitis suppurativa who completed the 54 weeks of study treatment within the originating parent Phase 3 studies (INCB 54707-301 \[NCT05620823\] or INCB 54707-302 \[NCT05620836\]).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/29/2025
Locations: Investigative Site US303, Phoenix, Arizona +171 locations
Conditions: Hidradenitis Suppurativa (HS)
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
Recruiting
Rollover study for participants from predetermined, Incyte-sponsored parent clinical trials of povorcitinib.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/29/2025
Locations: Investigative Site US086, Birmingham, Alabama +348 locations
Conditions: Hidradenitis Suppurativa (HS)
Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense
Recruiting
The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 16 weeks (Period 1) in adults with hidradenitis suppurativa, followed by a 16-week open-label extension period in which all participants will receive tibulizumab (Period 2)
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
05/19/2025
Locations: DelRicht LLC, Baton Rouge, Louisiana
Conditions: Hidradenitis Suppurativa (HS)
Participants with Mild to Moderate Hidradenitis Suppurativa Will Receive EVO101 a Topical Cream 0.1%
Recruiting
The goal of this clinical trial is to learn if drug EVO101 works to treat mild to moderate hidradenitis suppurativa in adults. The main questions it aims to answer are:
Does drug EVO101 lower the total number of lesion a participant has from the first visit to the last visit.
What medical problems do participants have when applying drug EVO101 Does a participant perceive a change in their hidradenitis suppurativa symptoms based on patient reported outcome questionnaires.
Participants will:
A... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/05/2024
Locations: Virginia Clinical Research, Inc., Norfolk, Virginia
Conditions: Hidradenitis Suppurativa (HS)
1 - 4 of 4